Long-acting Inhaled Bronchodilator and Risk of Vascular Events in Patients With Chronic Obstructive Pulmonary Disease in Taiwan Population

Ming-Jun Tsai, MD, PhD, Chung-Yu Chen, PhD, Yaw-Bin Huang, PhD, Hsiao-Chung Chao, MS, Chih-Jen Yang, MD, Pei-Jin Lin, PhD, and Yi-Hung Tsai, PhD

Abstract: A combination of long-acting anticholinergic agents (LAACs) and long-acting β2-adrenergic receptor agonist (LABA) is effective in improving lung function in chronic obstructive pulmonary disease (COPD) compared with monotherapy. However, evidence on whether this combination increases the incidence of stroke or other cardiac events remains sparse. The objective of the present study was to investigate the incidence of stroke and other cardiovascular diseases in COPD patients treated with LAAC, LABA, or a combination of the 2.

We conducted this population-based study using the Taiwan National Health Insurance Research Database (1997–2008), identifying COPD patients and their prescribed medication from the International Classification of Disease, Ninth Revision codes 490–492 or 496. A multivariate Cox proportional-hazards model was used to compare the risk of stroke and other cardiovascular diseases over the 11-year period after treatment with LAAC or LABA only or in combination.

Of the 596 COPD patients (mean age 70 y), 196 were treated with LAAC, 318 with LABA, and 82 were treated with a combination. The overall incidence of stroke (8.53%) significantly increased in the combination group compared with LAAC (2.04%) or LABA (1.26%) only. In the Cox regression analysis, the adjusted hazard ratio over the 11-year survey period for stroke in patients treated with the combination compared with LABA only was 1.04 (95% confidence interval, 1.06–2.09) and for LAAC, it was 0.31 (95% confidence interval, 0.02–2.32).

This cohort study using a large health insurance database showed that treating patients with COPD, with a combination of LAAC and LABA, may be associated with an increased hazard of stroke compared with treatment with either agent alone. We should be particularly cautious about comedication of LAAC and LABA in patients with COPD.

Abstract: aHR = adjust hazard ratio, cHR = crude hazard ratio, CI = confidence interval, COPD = chronic obstructive pulmonary disease, ICD9 = International Classification of Diseases Ninth Revision, ICS = inhaled corticosteroids, LAAC = long-acting anticholinergic agents, LABA = long-acting β2-adrenergic receptor agonist, LHID = Longitudinal Health Insurance Database, miRs = microRNAs, ncRNAs = noncoding RNA, NHIRD = National Health Insurance Research Database, VEGF = vascular endothelial growth factor.

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is a major cause of chronic morbidity and mortality worldwide. Bronchodilators are the primary treatment for COPD and include anticholinergics, β2-agonists, methylxanthines, and corticosteroids used alone or in combination.1 The effectiveness and safety of long-acting anticholinergic agents (LAACs) and long-acting β2-adrenergic receptor agonists (LABAs) have been described in meta-analyses2–3 or retrospective cohort studies4,5 reporting an imprecise reduction in mortality and a significantly lower risk for COPD exacerbations. Accumulated evidence has shown that a combination of LAAC and LABA is effective in improving lung function tests and quality of life compared with monotherapy in patients with COPD, particularly when the COPD is severe.6–9

However, from previous studies, there has been concern that LAAC and LABA drugs may increase hazard of cardiovascular and/or cardio-cerebrovascular complications, including heart failure, angina cardiac dysrhythmias, myocardial infarction, or stroke.10–13 In contrast, the results of the clinical trial and previous observational studies showed that the incidence rate and hazard of stroke or cardiac events were not significantly different between LAAC and LABA.14–17 Therefore, current evidences indicated cardiovascular or cardio-cerebrovascular safety is a matter of debate in patients with COPD using LAAC or LABA. In particular, it remains unclear whether a combination of LAAC with LABA or LABA with inhaled corticosteroids (ICS) increases the incidence of stroke or other cardiac events.17–19
The purpose of the present study was to compare, using the Taiwan National Health Insurance (NHI) Database, the hazard of stroke and other cardiovascular diseases arising from combination therapies LAAC/LABA or LABA/ICS with monotherapies of LABA or LAAC only in patients with COPD.

METHODS AND MATERIALS

Source of Data

This population-based retrospective cohort study was based on the Longitudinal Health Insurance Database (LHID) 2005, which included 1 million individuals randomly sampled from the 2005 Registry for Beneficiaries of Taiwan’s National Health Insurance Research Database (NHIRD). This database, provided by the National Health Research Institute, included data on outpatients, hospital inpatient care, ambulatory care, dental services and prescription drugs. In 1995, NHI, a government-run insurer with a single-payer insurance system, was established in Taiwan to ensure the health of the entire nation and to prevent social problems caused by poverty and diseases. By December 2008, 22.918 million individuals were enrolled in the program nationwide, with a coverage rate of 99.5% in Taiwan. There was no significant difference in sex distribution ($\chi^2 = 0.008$, df = 1, $P = 0.931$) between the patients in LHID 2005 and those in the original NHIRD. This study was approved by the Institutional Review Board of Kaohsiung Medical University Hospital on February 24, 2015 (KMU-IRB-EXEMPT-20150009). However, this retrospective descriptive study does not require patient consent according to the current rules in our Hospital and NHIRD.

Study Design

A cohort of adults diagnosed between 1997 and 2008 with first-time COPD (International Classification of Disease, Ninth Revision [ICD-9] codes: 490–492, 496; A-code: A323 and A325) was identified from LHID 2005. Otherwise, patients with COPD were included only if they had been diagnosed twice in our surveys. We excluded patients diagnosed with asthma (ICD-9: 493), pulmonary hypertension (ICD-9: 416.0), sleep apnea (ICD-9: 327.23, 780.57), pneumonia (ICD-9: 486, 507.0–507.8), or who were <18 years old at the date of first-time COPD diagnosis (which we took as the index date in our study). We also excluded patients diagnosed with stroke (ICD-9: 430–438), heart failure (ICD-9: 428), ventricular arrhythmia (ICD-9: 427, 785.0, 785.1), myocardial infarction (ICD-9: 410), or angina pectoris (ICD-9: 413) before the index date.

We divided the population of COPD patients into 3 groups according to the drug treatment received: LAAC only, LABA only, or a combination (LAAC/LABA or LABA/ICS). We selected the patients who were prescribed LAAC (tiotropium), LABA (salmeterol or formoterol), or a combination (salmeterol/fluticasone or formoterol/budesonide) between 1997 and 2008, and who had used either LAAC or LABA or LABA/ICS continuously over 1 year. The medication included had the following anatomical therapeutic chemical classifications: tiotropium handihaler (R03BB04), salmeterol (R03AC12), formoterol (R03AC13), salmeterol/fluticasone (R03AK06), and formoterol/budesonide (R03AK07). To decreasing selection bias due to LABA was approved using in NHI earlier than LAAC or LABA/ICS, LABA group was selected as the control group in this study (Table 1).

Patients were followed from index date until one of the following events occurred: diagnosis of stroke, other cardiovascular events and death occurred, December 31, 2008 was reached, or the patient withdrew from the NHI. The baseline history of comorbidities was identified by diagnostic codes from one outpatient diagnosis or inpatient diagnosis before the index date. Comorbidities included hypertension (ICD-9: 401–405), diabetes mellitus (ICD-9: 250), hyperlipidemia (ICD-9: 272), and tuberculosis (ICD-9: 010.90). In addition, we evaluated demographic characteristics for patients with the different treatments, including sex and age. The use of concomitant drugs that might influence the efficacy of LAAC or LABA was identified according to the prescriptions within 1 year before index date. These drugs included LAAC, LABA, short-acting anticholinergics, short-acting $\beta_2$-adrenergic receptor agonists, ICS, xanthenes, or oral steroid medication.

Outcomes

The main outcomes evaluated were admission to hospital for stroke, heart failure, ventricular arrhythmia, myocardial infarction, or angina pectoris, based on the primary or secondary diagnoses (ICD-9). The incidence was calculated for each disease outcome. In addition, the secondary outcomes were combined into 2 composite endpoints: cardiovascular events and cardiovascular events and cardio-cerebrovascular events. Cardiovascular events included heart failure, ventricular arrhythmia, myocardial infarction, and angina pectoris. Cardio-cerebrovascular events included the cardiovascular events and stroke.

Statistics

The hazard of outcomes during the 11-year follow-up was investigated for each treatment: LAAC or LABA only or a combination. Continuous and categorical variables were compared between each group with Student $t$ test and analysis of variance (ANOVA), as appropriate. A post hoc Scheffe analysis was used. All data were expressed as frequency (percentage) and mean ± standard deviation (SD). The incidence of outcomes with the different treatments was calculated using the total number of

| Classification | Drug | Time of Admission |
|----------------|------|-------------------|
| Long-acting inhaled anticholinergic (LAAC) | Tiotropium | 2003.12.01 |
| Long-acting inhaled $\beta_2$-adrenergic receptor agonist (LABA) | Salmeterol | 1997.02.01 |
| | Formoterol | 2001.10.01 |
| LABA/inhaled corticosteroids (ICS) | Salmeterol/fluticasone | 2002.03.01 |
| | Formoterol/budesonide | 2002.04.01 |

ICS = inhaled corticosteroids, LAAC = long-acting anticholinergics, LABA = long-acting $\beta_2$-agonists.
results that occurred for each disease from 1997 to 2008 as numerator and the total number of cases of each disease as denominator. The onset time of outcomes was calculated for the different treatments as the average duration from index date to first-time diagnosis of the outcome in the 11-year survey. A Cox proportional-hazards model was used to assess the risk of each outcome during the follow-up period for the LAAC only or combination treatment groups compared with that for the LABA-only group. The multivariable model was adjusted for age, sex, comorbidities, and comedication. Analyses and calculations were performed using SAS ver. 9.3 (SAS Institute, Inc., Cary, NC), and statistical significance was inferred at a 2-sided P value of < 0.05.

RESULTS

Characterization of the Study Participants in 3 Groups

In total, 596 patients used at least one of LAAC (n = 196), LABA (n = 318), LAAC/LABA, or LABA/ICS (n = 82) continuously for at least 1 year, as shown in Figure 1. Demographic information including age, sex, comorbidity, and medication use is shown in Table 2. There were no statistically significant differences between the 3 groups in age, sex, and comorbidity, with a mean age of about 70 and a male predominance (about 86%) in all the groups.

Incidence and Onset Time of Cardiac Failure, Arrhythmia, Myocardial Infarction, Angina, or Stroke in the 3 Groups

The incidences of different vascular events among the patients with COPD after more than a year of taking LAAC, LABA, and combination are shown in Table 3. From the long-term survey, there was no statistically significant difference between the 3 groups of COPD patients in developing cardiovascular diseases. However, the incident rates of stroke over the 11-year survey in the LAAC only, LABA only, and combination groups were 2.04%, 1.26%, and 8.53%, respectively—a difference that was statistically significant (P = 0.0033).

Table 4 shows that the mean time to onset of cardiovascular events was shortest for the combination group and longest for the LABA-only group, although these differences were not statistically significant. However, the mean time to onset of strokes did differ significantly between the groups, being 898.39 ± 9.6 days for the LAAC-only group, 1495.20 ± 9.06 days for the LABA-only group, and 1147.52 ± 4.26 days for the combination group (P < 0.0001). Scheffe post hoc test also showed that patients in the LAAC group had shorter onset time of strokes than those in the LABA-only or combination group.

Hazard Ratio of Outcomes Comparing the Different Treatment Groups

Comparing the LAAC-only group with the LABA-only group, the observed crude hazard ratio (cHR) for cardiovascular events was 0.55 (95% confidence interval [CI], 0.21–1.06) and adjusted hazard ratio (aHR) was 0.49 (95% CI, 0.14–1.01). A similar trend was seen for cardiovascular or cerebrovascular events or each outcomes comparing the LAAC-only and LABA-only groups, as shown in Table 5.

Comparing the combination group with the LABA-only group showed an increased hazard of cardiovascular events: cHR 1.27 (95% CI, 1.03–2.89) and aHR 1.53 (95% CI, 1.03–2.89). Cardio-cerebrovascular events also showed increased hazard: cHR 1.14 (95% CI, 1.02–2.88) and aHR 1.18 (95% CI, 1.04–2.93). In particular, the risk of stroke was greater in the combination group: cHR 1.03 (95% CI, 1.01–2.93) and aHR 1.04 (95% CI, 1.06–2.99).

DISCUSSION

The present study mainly found LAAC/LABA or LABA/ICS was associated with an increased risk of cardiovascular events or stroke than with monotherapies of LABA or LAAC only in patients with COPD. Previous cohort studies had reported risks of vascular diseases of treatment with LABA or LAAC only in COPD.4,11,18,20,21 Wang et al22 reported that ipratropium had an increased risk of stroke than nonusers in COPD patients, with populations similar to that of the present study. However, the design of our study included 596 COPD patients without other pulmonary diseases, and we subdivided our population into 3 groups (LAAC-only users, LABA-only users, and patients receiving a combination of LAAC/LABA or LABA/ICS) to evaluate the risk of outcome.

The results showed that the risks of cardiovascular events or stroke were higher with the combination treatment than with LABA only, but they were not observed for LAAC-only than LABA-only group. These results were similar to those of Rodrigo et al, who reported that LAAC did not increase the risk of cardiovascular and cerebrovascular events compared with LABA.23 Nevertheless, from previous research, there was limited information about evaluating hazards of cardiovascular and cerebrovascular events between ICS/LABA combination and LABA or LAAC only. Otherwise, recent meta-analysis and researches have shown that combination of umeclidinium and vilanterol or indacaterol and glycopyrronium may not increase the risk of cardiovascular or other serious side effects.9,24,25 This difference from our results may be due to the different
combination treatment in our study with other studies. From our results, especially for stroke, the combination group had a higher incident rate than the LAAC-only or LABA-only groups. More clinical evidence is required to demonstrate the safety of cardiovascular and cerebrovascular events in COPD patients treated with combination treatment.

The main biological mechanism of vascular diseases in COPD patients using LAAC or LABA is still unclear. From previous data, COPD is known as chronic inflammatory process including lungs, metabolic syndrome, or cardiovascular diseases. The potential role of inflammatory processes plays an important role in mediating systemic cardiovascular disease in COPD. Previous researches showed that LAAC or LABA-effected inflammatory cytokines might be the mechanism of high risk of vascular disease. Combination of LAAC/LABA or LABA/ICS may enhance the level of affected inflammatory cytokines. Otherwise, microRNAs (miRs) or regulatory noncoding RNAs (ncRNAs) represent critical regulators of cardiovascular or cerebrovascular function and play important roles in basic regulatory mechanisms of cells (including inflammation). Furthermore, miRs are involved in the pathogenesis of lung diseases such as asthma and COPD. In 2010, Sato et al had reported that miR-146 expression in COPD patients after stimulation by proinflammatory cytokines is less than its rate compared with patients without COPD. From current evidence, miRs are dysregulated in cardiac disease and have emerged as promising therapeutic targets. There is limited information about LAAC, LABA, or combination on the influence level of miRNA expression; more direct evidence is required to conduct the mechanism and emerging functional role of miRNA in COPD patients treated with bronchodilators, especially in different treatment strategies.

From a review, Matarese and Santulli indicated that angiogenesis is a central component of COPD, and angiogenesis is also an important component of pathophysiology in cancer and other disorders. Angiogenesis requires a tightly coordinated guidance from a variety of regulators; vascular endothelial growth factor (VEGF) is one of most important players. VEGF

### TABLE 2. Demographic Characteristics, Comorbidity, and Comedication of Chronic Obstructive Pulmonary Disease in the Retrospective Cohort Study

| Characteristics | LAAC (n = 196) | LABA (n = 318) | Combination (n = 82) | P  |
|-----------------|---------------|---------------|---------------------|----|
| Sex, n (%)      |               |               |                     |    |
| Male            | 176 (89.80)   | 274 (86.16)   | 73 (89.02)          | 0.4383 |
| Female          | 20 (10.20)    | 44 (13.84)    | 9 (10.98)           |    |
| Age (mean, SD)  | 70.29 (±10.78)| 70.44 (±12.04)| 70.50 (±11.02)      | 0.9862 |
| Comorbidity     |               |               |                     |    |
| Hypertension    | 80 (40.82)    | 117 (36.79)   | 35 (42.68)          | 0.4996 |
| Diabetes        | 43 (21.94)    | 78 (24.53)    | 22 (26.83)          | 0.6488 |
| Tuberculosis    | 11 (5.61)     | 28 (8.81)     | 8 (9.76)            | 0.3221 |
| Hyperlipidemia  | 72 (36.73)    | 104 (32.70)   | 29 (35.37)          | 0.6342 |
| Comedications   |               |               |                     |    |
| LAAC            | —             | 12 (3.77)     | —                   | —   |
| SAAC            | 45 (22.96)    | 99 (31.13)    | 26 (31.71)          | 0.0818 |
| LABA            | 2 (1.02)      | —             | —                   | —   |
| SABA            | 63 (32.14)    | 118 (37.11)   | 38 (46.34)          | 0.0521 |
| ICS             | 2 (1.02)      | 4 (1.26)      | —                   | —   |
| LABA/ICS        | 14 (7.14)     | —             | —                   | —   |
| SABA/ICS        | 45 (22.96)    | 78 (24.53)    | 31 (37.80)          | <0.0001 |
| Xanthines       | 161 (82.14)   | 252 (79.25)   | 64 (78.05)          | 0.7463 |
| Oral steroids   | 58 (29.59)    | 101 (31.76)   | 29 (35.37)          | 0.0062 |

ICS = inhaled corticosteroids, LAAC = long-acting anticholinergics, LABA = long-acting β2-agonists, SAAC = short-acting anticholinergics, SABA = short-acting β2-agonists, SD = standard deviation.

### TABLE 3. Cumulative Incidence of Cardiovascular or Cerebrovascular Events Between Inhaled Bronchodilators in Follow-up Period Stratified by LAAC Only, LABA Only, and Combination (LAAC/LABA or LABA/ICS)

| Drug               | LAAC No. (%) | LABA No. (%) | Combination No. (%) | P  |
|--------------------|--------------|--------------|---------------------|----|
| Heart failure      | 6 (3.06)     | 9 (2.83)     | 3 (3.66)            | 0.8446 |
| Ventricular arrhythmia | 6 (3.06)  | 13 (4.08)    | 2 (2.43)            | 0.7803 |
| Myocardial infarction | 2 (1.02)  | 7 (2.20)     | 1 (1.22)            | 0.7405 |
| Angina pectoris    | 3 (1.53)     | 8 (2.52)     | 2 (2.43)            | 0.7296 |
| Stroke             | 4 (2.04)     | 4 (1.26)     | 7 (8.53)            | 0.0033* |

LAAC = long-acting anticholinergics, LABA = long-acting β2-agonists.

*P < 0.05.
has higher expression in COPD patients and smokers than the general population, and this expression is associated with enlargement of arterial wall and hypoxia. Otherwise, recent evidence suggests that VEGF also acts directly on neuronal progenitor cells to produce neurogenic effect. There were previous studies which showed that combination (ICS/LABA) may enhance decreasing expression of VEGF. Therefore, combination treatments of LAAC/LABA or LABA/ICS may therefore be associated with enhancing the clinical effect of COPD control, and may also result in decreasing neurogenic effects in the combination group than in the single-treatment groups by decreasing VEGF expression in the brain and the lungs. However, currently unavailability evidence of LAAC or LAAB, or combination exerts a central or systemic angiogenic effect or VEGF expression in COPD patients; further research is warranted to examine the existence of this mechanism, or information bias may occur in this study by using large health insurance database. Patients using LABA, LAAC, or combination over 1 year were included in the analysis, which could cause selection bias for patients who are using for less than 1 year or who are intermittent users. Hospital and outpatient visit claim data were used to determine the diagnoses, medical treatment, and duration of treatment. Moreover, the possibility of selection bias and misclassification cannot be completely ruled out because some patients may not have used their prescriptions. Otherwise, accuracy of the information used in this study, such as for prescribed drugs and comorbidities, has not been validated, which could also leave room for information bias. Third, the patients in our sample were Han Chinese; generalization of the results to other ethnic or racial groups must therefore be made with caution. Lastly, because of prevalent medication use of LABA or LAAC, or combination, analysis of these medications on the vascular risk was limited by the population and sample size. Therefore, future studies are recommended to recruit a larger COPD population to further investigate the correlation between bronchodilators and safety of vascular disease.

**CONCLUSIONS**

This study retrospectively used a large health insurance database and Cox hazard modeling to evaluate the risk of stroke...
and cardiovascular diseases in 3 different COPD treatment groups (LAAC only, LABA only, or a combination of LAAC/LABA or LABA/ICS). Our results suggest that the combination treatment may increase stroke risk compared with the single-drug treatment. COPD patients treated clinically with a combination of LAAC/LABA or LABA/ICS should be monitored more for the hazard of stroke and cardiovascular events.

REFERENCES

1. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for chronic obstructive Lung Disease (OLD) Workshop summary. Am J Respir Crit Care Med. 2001;163:1256–1276.

2. Salpeter SR, Buckley NS, Salpeter EE. Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med. 2006;21:1011–1019.

3. Barr RG, Bourbeau J, Camargo CA, et al. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax. 2006;61:850–862.

4. De Lusie C, Lanes SF, Jacobsen J, et al. Cardiovascular and respiratory hospitalizations and mortality among users of tiotropium in Denmark. Eur J Epidemiol. 2007;22:267–272.

5. Jara M, Lanes SF, Wentworth C 3rd et al. Comparative safety of long-acting inhaled bronchodilators: a cohort study using the UK THIN primary care database. Drug Saf. 2007;30:1151–1160.

6. Verhamme KM, Afonso AS, van Noord C, et al. Tiotropium Handihaler and the risk of cardio- or cerebrovascular events and mortality in patients with COPD. Palm Pharmacol Ther. 2012;25:19–26.

7. Lindgren A. Stroke genetics: a review and update. J Stroke. 2014;16:114–123.

8. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364:1093–1103.

9. Mochizuki H, Nanjo Y, Kawate E, et al. beta2-adrenergic receptor haplotype may be associated with susceptibility to desensitization to long-acting beta2-agonists in COPD patients. Lung. 2012;190:411–417.

10. Ferri C. Strategies for reducing the risk of cardiovascular disease in patients with chronic obstructive pulmonary disease. High Blood Press Cardiovasc Prev. 2015;22:103–111.

11. Greenson AJ, Croxford R, Calzavara A, et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med. 2013;173:1175–1185.

12. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease. JAMA. 2008;300:1439–1450.

13. Lee TA, Pickard AS, Au DH, et al. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med. 2008;149:380–390.

14. Oba Y, Zaza T, Thameem DM. Safety, tolerability and risk benefit analysis of tiotropium in COPD. Int J Chron Obstruct Pulmon Dis. 2008;3:575–584.

15. Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium-the FDA’s conclusions. N Engl J Med. 2010;363:1097–1099.

16. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543–1554.

17. Keating GM. Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease. Drugs. 2012;72:273–300.

18. Mara J, Wentworth C 3rd, Lanes S. A new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPD. BMJ Open. 2012;2:1–10.

19. Rodrigo GJ, Neffen H. A systematic review of the efficacy and safety of a fixed-dose combination of umeclidinium and vilanterol for the treatment of COPD. Chest. 2015;148:397–407.

20. Celli B, Decramer M, Leimer I, et al. Cardiovascular safety of tiotropium in patients with COPD. Chest. 2010;137:20–30.

21. Stanbrook MB. Therapeutics. Review: tiotropium does not increase risk for cardiovascular events in chronic obstructive pulmonary disease. Ann Intern Med. 2010;153:J1C–J1C-3.

22. Wang MT, Tsai CL, Lo YW, et al. Risk of stroke associated with inhaled ipratropium bromide in chronic obstructive pulmonary disease: a population-based nested case-control study. Int J Cardiol. 2012;158:279–284.

23. Rodrigo GJ, Castro-Rodriguez JA, Nannini LJ, et al. Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis. Respir Med. 2009;103:1421–1429.

24. Rodrigo GJ, Plaza V. Efficacy and safety of a fixed-dose combination of indacaterol and glycopyrronium for the treatment of COPD: a systematic review. Chest. 2014;146:309–317.

25. Rodrigo GJ, Plaza V. Efficacy and safety of indacaterol and glycopyrronium in COPD: an update. Chest. 2014;146:675.

26. Barbara Góralczyk, Ewelina Dreła, Krzysztof Góralczyk, et al. Angiogenesi in chronic obstructive pulmonary disease. Med Bio Sci. 2012:26:19–25.

27. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107:1514–1519.

28. Wang Q, Tang XN, Yenari MA. The inflammatory response in stroke. J Neuroimmunol. 2007;184:53–68.

29. Powrie DI, Wilkinson TM, Donaldson GC, et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J. 2007;30:472–478.

30. Sin DD, Man SF, Marciniuk DD, et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177:1207–1214.

31. Santulli G, Iacarrino G, De Luca N, et al. Atrial fibrillation and microRNAs. Front Physiol. 2014;24:15.

32. Wronska A, Kurkowska-Jastrzebska I, Santulli G. Application of microRNAs in diagnosis and treatment of cardiovascular disease. Acta Physiol (Oxf). 2015;213:60–83.

33. Charan Reddy KV. Regulatory noncoding RNAs in cardiovascular disease: shedding light on ‘dark matter’. J Cardiovasc Dis. 2015;3:301–307.

34. Ebrahimi A, Sadroddiny E. MicroRNAs in lung diseases: recent findings and their pathophysiological implications. Palm Pharmacol Ther. 2015;34:55–63.

35. Sato T, Liu X, Nelson A, et al. Reduced miR-146a increases prostaglandin E2 in chronic obstructive pulmonary disease fibroblasts. Am J Respir Crit Care Med. 2010;182:1020–1029.

36. Matarese A, Santulli G. Angiogenesi in chronic obstructive pulmonary disease: a translational appraisal. Transl Med UnitSu. 2012;30:49–56.

37. Ruan L, Wang B, ZhuGe Q, et al. Coupling of neurogenesis and angiogenesis after ischemic stroke. Brain Res. 2015;1623:166–173.
38. Wang K, Liu CT, Wu YH, et al. Budesonide/formoterol decreases expression of vascular endothelial growth factor (VEGF) and VEGF receptor 1 within airway remodelling in asthma. Adv Ther. 2008;25:342–354.

39. Skevaki CL, Christodoulou I, Spyridaki IS, et al. Budesonide and formoterol inhibit inflammatory mediator production by bronchial epithelial cells infected with rhinovirus. Clin Exp Allergy. 2009;39:1700–1710.

40. Volonaki E, Psarras S, Xepapadaki P, et al. Synergistic effects of fluticasone propionate and salmeterol on inhibiting rhinovirus-induced epithelial production of remodelling-associated growth factors. Clin Exp Allergy. 2006;36:1268–1273.

41. Tsukahara T, Usui H, Taniguchi T, et al. Characterization of muscarinic cholinergic receptors in human and dog cerebral arteries. Stroke. 1986;17:300–305.